

2020 SABCS Disclosures

Program #	First Name	Last Name	Degrees	Disclosure Information
Abstract Reviewer	Kathy S.	Albain	MD	Dr. Albain has disclosed contracted research to the institution with I Spy 2 Consortium and AZ/Daiichi Sankyo. She has also disclosed other member IDMC and Seattle Genetics. These financial relationships will not impact her ability to present an unbiased abstract review.
Abstract Reviewer	Kimberly	Allison	MD	Dr. Allison has disclosed salary with Mammoth. She has also disclosed royalties with Lilly. These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Reviewer	Carey K.	Anders	MD	Dr. Anders has disclosed royalties from UpToDate, Jones and Bartlett. He has also disclosed consulting fees with Genentech, IPSEN, Seattle Genetics and AstraZeneca. Dr. Anders has also disclosed contracted research with Lilly, Merck, Seattle Genetics, Nektar and Tesaro/GSK. These financial relationships will not impact his ability to present an unbiased presentation. He intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
SABCS Strategic Planning; Abstract Reviewer	Fabrice	André	MD, PhD	Prof. André has disclosed contracted research with Novartis, AstraZeneca, Pfizer, Lilly, and Roche.
Executive/Program Planning Committee Member; SABCS Strategic Planning; Molecular Biology in Breast Oncology Workshop Moderator	Carlos L.	Arteaga	MD	Dr. Arteaga has disclosed consulting fees from Novartis, Lilly, Merck, Sanofi, Daiichi Sankyo, PUMA Biotechnology, RADIUS, TAIHO Oncology, Petra Pharma, Immunomedics, G1 Therapeutics, Athenex, Abbvie, H3Biomedicine, OrigiMed, and Clovis. He has also disclosed ownership interest with Provista and Y-TRAP and contracted research receiving research grants from Pfizer, Lilly, and TAKEDA. He has also disclosed ownership interest in Provista, and Y-Trap and has an advisory role with Novartis, Lilly, TAIHO Oncology, Daiichi Sankyo, Merck, AstraZeneca, OrigiMed, and Immunomedics. He is on the scientific advisory board for Komen Foundation and has disclosed minor stock options in Provista and Y-TRAP. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Banu	Arun	MD	Dr. Arun has disclosed contracted research paid to the institution with AstraZeneca, Invitae and AbbVie. These financial relationships will not impact her ability to present an unbiased presentation. Dr. Arun intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
Special Session Speaker	Philippe	Autier	MD, MPH, PhD	Prof. Autier has no relevant financial relationships with commercial interests to disclose.
Year in Review Speaker; Abstract Reviewer	Justin	Balko	PhD, PharmD	Dr. Balko has disclosed contracted research with Genentech, Bristol Myers Squibb and Incyte. These financial relationships will not impact his ability to present an unbiased presentation. Dr. Balko intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Debate Presenter	Judith	Balmaña	MD, PhD	Dr. Balmaña has disclosed consulting fees with AstraZeneca and contracted research with AstraZeneca. These financial relationships will not impact her ability to present an unbiased presentation.
Program Planning Committee Member; Translational Science Forum Speaker	Aditya	Bardia	MBBS (MD), MPH	Dr. Bardia has disclosed consulting fees from Novartis, Pfizer, Daiichi/Astra-Zeneca, Sanofi, Genentech/Roche, Radius Health, Merck, Eli Lilly, PUMA and Immunomedics. He has also disclosed contracted research from Institution Funding (as PI): Novartis, Pfizer, Sanofi, Genentech/Roche, Radius Health, Merck and Immunomedics. Dr. Bardia intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Abstract Reviewer	Philippe	Bedard	MD, FRCPC	Dr. Bedard has disclosed contracted research with AstraZeneca, BristolMyersSquibb, Genentech/Roche, GlaxoSmithKline, Merck, Lilly, Nektar, Novartis, PTC Therapeutics, Sanofi, Seattle Genetics, Servier, SignalChem Life Sciences and Zymeworks. He has also disclosed other uncompensated advisory with BMS, Merck and Seattle Genetics.
Abstract Reviewer	Jennifer	Bellon	MD	Dr. Bellon has disclosed royalties with UpToDate (Wolters Kluwer). She has also disclosed fees for non-cme services received directly from commercial interest or their agents from educational consultant for Varian. These financial relationships will not impact her ability to present an unbiased presentation.

2020 SABCS Disclosures

Educational Session Speaker	Andrea	Bild	PhD	Dr. Bild has no relevant financial relationships with commercial interests to disclose.
Staff	Susan	Binger		Ms. Binger has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Alex	Bishop	BSc, DPhil	Dr. Bishop has no relevant financial relationships with commercial interests to disclose.
Abstract Section Chair; Abstract Reviewer	Anne	Blaes		Dr. Blaes has no relevant financial relationships with commercial interests to disclose.
Abstract Section Chair; Abstract Reviewer	Melissa	Bondy		Dr. Bondy has no relevant financial relationships with commercial interests to disclose.
Educational Session Speaker	Simon	Boulton	PhD	Prof. Boulton has disclosed salary with Artios Pharma Ltd. and consulting fees with COR2ED. He has also disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with Artios Pharma Ltd. These financial relationships will not impact his ability to present an unbiased presentation.
Clinical Research Workshop Speaker	Thomas M.	Braun	PhD	Dr. Braun has no relevant financial relationships with commercial interests to disclose.
Abstract Section Chair; Abstract Reviewer	Andrew	Brenner		Dr. Brenner has disclosed receipt of intellectual property rights/patent holder with NanoTx Therapeutics and consulting fees with Alamab Therapeutics, Vascular Biogenics and Plus Therapeutics. He has also disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with NanoTx Therapeutics and Plus Therapeutics. These financial relationships will not impact his ability to present an unbiased presentation.
Program Planning Committee Member	Leticia Z.	Bresnahan		Ms. Bresnahan has no relevant financial relationships with commercial interests to disclose.
Abstract Section Chair; Abstract Reviewer	Powel	Brown	MD, PhD	Dr. Brown has disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with Genetex (<1% of total stock). These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Adam	Brufsky	MD, PhD	Dr. Brufsky has disclosed consulting fees with Amgen, Sanofi, Lilly, Novartis, Roche, Immunomedics, Pfizer, Seattle Genetics, AstraZeneca and Sandoz. These financial relationships will not impact his ability to present an unbiased presentation.
Clinical Science Forum Speaker; Abstract Reviewer	Mark E.	Burkard	MD, PhD	Dr. Burkard has disclosed consulting fees with Strata Oncology and Novartis. He has also disclosed contracted research with Abbvie, Genentech, Puma, Arcus, Apollomics and Loxo Oncology. These financial relationships will not impact his ability to present an unbiased presentation. Dr. Burkard intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Educational Session Speaker	David	Cameron	MBBS, MD	Prof. Cameron has disclosed consulting fees with IDMC work for Novartis and Synthon, Advisory board for Roche and Seattle Genetics, presenting data (CME accredited) for Lilly. No personal income gained from this work. These financial relationships will not impact his ability to present an unbiased presentation. Prof. Cameron intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
McGuire Committee, SABCS Strategic Planning, Educational Session Speaker	Lisa A.	Carey	MD	Dr. Carey has disclosed consulting fees from Samsung Bioepis, Novartis and Seattle Genetics. As an IDMC, Lilly USA and Breast International Group. As an advisory board G1 Therapeutics, Novartis and Immunomedics. As a steering committee Novartis and Immunomedics. Please note that Dr. Carey does not receive any compensation. All contracts are with UNC for Dr. Carey's time. Dr. Carey does not have signatory authority over an UNC account receiving these contracted monies. Her spouse is Dr. Matt Ewend, MD has disclosed a neural stem cell therapy patent with Falcon Therapeutics and serves on the board- receives no compensation. Dr. Carey intends to reference unlabeled/unapproved uses of drugs or products in her presentation.

2020 SABCS Disclosures

Executive/Program Planning Committee Member	Gary	Chamness	PhD	Dr. Chamness has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Jenny	Chang	MD	Dr. Chang has no relevant financial relationships with commercial interests to disclose.
Educational Session Speaker	Mariana	Chavez Mac Gregor	MD, MSc	Dr. Chavez Mac Gregor has disclosed consulting fees from Pfizer, AstraZeneca, Abbott, Novartis and Roche. These financial relationships will not impact her ability to present an unbiased presentation.
Program Planning Committee Member, Basic Science Forum Moderator	Chonghui	Cheng	MD, PhD	Dr. Cheng has no relevant financial relationships with commercial interests to disclose.
Educational Session Speaker	Lewis	Chodosh	MD, PhD	
Educational Session Speaker	Robert	Clarke	PhD	
Abstract Reviewer	Robert	Coleman	MBBS, MD, FRCP	München, Scancell, Biocon and Carrick. He has also disclosed fees for non-CME services received directly from commercial interest or their agents with Amgen. Prof. Coleman has also disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with Inbiomotion-biomarker. These financial relationships will not impact his ability to present an unbiased
Clinical Research Workshop Speaker	Deborah	Collyar		
Educational Session Speaker	Javier	Cortes	MD, PhD	Dr. Cortes has disclosed consulting fees with Roche, Celgene, Astrazeneca, Cellestia, Biothera, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Atehenex, Polyphor, Lilly, Servier, Merck, GSK, Leuko, Bioasis, Clovis, and Boehringer. He has also disclosed contracted research with Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardanth Health, Merck Sharp&Dohme, Pfizer, Piquor Therapeutics, Puma C and Queen Mary University of London. Dr. Cortes has also disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with MedSIR. He has also disclosed other Honoraria with Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme and Daiichi Sankyo. These financial relationships will not impact his ability to present an unbiased presentation.
Mini-Symposia Moderator	Katherine	Crew	MD, MS	
Abstract Reviewer	Richard	Crownover		
Program Planning Committee Member	Bonner M.	Cutting		Ms. Cutting has no relevant financial relationships with commercial interests to disclose.
McGuire Committee	Nancy E.	Davidson	MD	Dr. Davidson has disclosed a salary with Fred Hutchinson Cancer Research Center and other with the board of directors for Ludwig Cancer Research and co-editor in chief of oncology. These financial relationships will not impact her ability to present an unbiased presentation.
	Karin	de Visser	PhD	
Abstract Reviewer	Carsten	Denkert	MD	Prof. Denkert has disclosed consulting fees with Roche, Novartis, Daiichi and Molecular Health. He has also disclosed contracted research with Myria. Prof. Denkert has also disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with Sividon Diagnostics (now Myriad). These financial relationships will not impact his ability to present an unbiased presentation.

2020 SABCS Disclosures

Program Planning Committee Member, Educational Session	Rebecca	Dent	MD, MSc	Dr. Dent has disclosed consulting fees from Astra Zeneca, Eisai, Lilly, Merck, Novartis, Pfizer and Roche. She has also disclosed other conference travel, Astra Zeneca, Merck, Pfizer and Roche. These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Reviewer	Christine	Desmedt	PhD	Prof. Desmedt has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Emilia	Diego	MD	Dr. Diego has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Nora	Disis	MD	Dr. Disis has disclosed royalties and receipt of intellectual property rights/patent holder with University of Washington. She has also disclosed contracted research with Pfizer, Bavarian Nordisk, Janssen, EMD Sorono and Precigen. Dr. Disis has also disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with Epithany. These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Reviewer	Susan	Domchek		Dr. Domchek has disclosed consulting fees and contracted research with AstraZeneca. These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Reviewer	Mitch	Dowsett	PhD, FMedSci	Dr. Dowsett has disclosed consulting fees from Radius, G1 Therapeutics, AbbVie and Lilly. He has also disclosed fees for non-CME services received directly from commercial interest or their agents with NanoString. Dr. Dowsett has also disclosed other Institute of Cancer Research Rewards for Inventors Scheme: Abiraterone. These financial relationships will not impact his ability to present an unbiased presentation.
Panelist	Peter	Dubsky	MD, PhD	Prof. Dubsky has disclosed consulting fees from AstraZeneca, Merck and Roche (via Hirslanden Klinik St. Anna). He has also disclosed contracted research with Agendia and Cepheid/Danaher (via ABCSG). These financial relationships will not impact his ability to present an unbiased presentation. Prof. Dubsky intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
SABCS Strategic Planning, Clinical Science Forum Moderator; Abstract Reviewer	Matthew J.	Ellis	MB, BChir, BSc, PhD, FRCP	Dr. Ellis has disclosed royalties from Bioclassifier, LLC and receipt of intellectual property rights/patent holder with PAM50, Prosigna and NanoString. He has also disclosed consulting fees from G1 Therapeutics, Foundation Medicine and Lilly and ownership interest in Bioclassifier LLC (manages Prosigna IP). These financial relationships will not impact his ability to present an unbiased presentation. Dr. Ellis intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Abstract Reviewer	W. Phil	Evans	MD	Dr. Evans has no relevant financial relationships with commercial interests to disclose.
Clinical Research Workshop Speaker	Oluwadamilola	Fayanju	MD, MA, MPHs, FACS	Dr. Fayanju has no relevant financial relationships with commercial interests to disclose.
Executive Program Planning Committee Member; SABCS Program Planning Committee Member, Educational Session Moderator	Margaret	Foti	PhD, MD (hc)	Dr. Foti has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Suzanne	Fuqua	PhD	Dr. Fuqua has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Patricia	Ganz	MD	Dr. Ganz has disclosed royalties with Up-To-Date as a Section Editor. She has also disclosed consulting fees with Blue Note Therapeutics for developing an app for psychosocial support of patients. Dr. Ganz has also disclosed ownership interest (stocks, stock options or other ownership interest excluding diversified mutual funds): her husband is Medical Director of Intrinsic Life Sciences, for work related to iron regulation. These financial relationships will not impact her ability to present an unbiased presentation.
Program Planning Committee Member; SABCS Strategic Planning; Abstract Session	Judy E.	Garber	MD, MPH	Dr. Garber has disclosed consulting fees from Helix Genetics and contracted research from Ambray Genetics and Myriad Genetics. She has also disclosed other consultant, no funds for Konica Minolta. These financial relationships will not impact her ability to present an unbiased presentation.

2020 SABCS Disclosures

Abstract Reviewer	David	Gius	MD, PhD	Dr. Gius has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Shom	Goel	MD, PhD	Dr. Goel has disclosed consulting fees with Eli Lilly, Novartis and G1 Therapeutics. He has also disclosed contracted research with Eli Lilly and G1 Therapeutics. These financial relationships will not impact his ability to present an unbiased presentation.
SABCS Strategic Planning, Educational Session Moderator; Abstract Section	Matthew P.	Goetz	MD	Prof. Goetz has disclosed consulting fees from Genomic Health, Lilly, Biovica, Novartis, Semonix, Context Pharm, Pfizer and Biotheranost and contracted research for Pfizer, Lilly. These financial relationships will not impact his ability to present an unbiased presentation.
Educational Session Speaker	Pamela	Goodwin	MD, MSc	Dr. Goodwin has disclosed contracted research with EPIC Science provides CTC assays for a study that is funded through other sources. These financial relationships will not impact her ability to present an unbiased presentation. She intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
Program Planning Committee Member, Panelist; Abstract Reviewer	William	Gradishar	MD	Dr. Gradishar has disclosed consulting fees with AstraZeneca, Lilly, Pfizer, MacroGenics, Genomic Health and Puma.
Abstract Reviewer	Joe	Gray	PhD	Prof. Gray has disclosed royalties with the University of California with Abbott and the Oregon Health and Science Institute from PDX Pharma. He has also disclosed receipt of intellectual property rights/patent holder with Oregon Health and Science University and the University of California. Prof. Gray has also disclosed contracted research with SBIR funding from Quantitative Imaging and PDX Pharma. He has also disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with Abbott Diagnostics, AbbVie, Alphabet, Amazon, Amgen, Ani Pharma, Apple Corporation, Berkshire Hathaway, Cameco, Chevron, Cisco, Clorox, Colgate-Palmolive, Conoco Phillips, Crown Castle, Devon Energy, Disney and Exxon. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Valentina	Guarneri	MD, PhD	Prof. Guarneri has disclosed fees for non-CME services received directly from commercial interest or their agents with Eli Lilly (advisory board, speaker's bureau) and Novartis (advisory board, speaker's bureau). These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Reviewer	Carolina	Gutierrez		Dr. Gutierrez has no relevant financial relationships with commercial interests to disclose.
Year in Review Speaker	Erika	Hamilton	MD	Dr. Hamilton has disclosed consulting fees paid to the institution with Pfizer, Genentech/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana Therapeutics, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, Black Diamond and NanoString. She has also disclosed research/clinical trial support paid to the institution from Seattle Genetics, Puma, AstraZeneca, Hutchinson MediPharma, OncoMed, MedImmune, StemCentrx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millenium, TapImmune, Lilly, BerGenBio, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, MacroGenics, Abbvie, Immunomedics, FujiFilm, Effector, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceutical, EMD Serono, Daiichi Sankyo, ArQule, Syros, Clovis, Cytomx, InventisBio, Deciphera, Unum Therapeutics, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback Therapeutics, Compugen, G1 Therapeutics, Karyopharm Therapeutics and Torque Therapeutics. These financial relationships will not impact her ability to present an unbiased presentation.

2020 SABCS Disclosures

Abstract Reviewer	Nadia	Harbeck	MD, PhD	Prof. Harbeck has disclosed consulting fees with Astra Zeneca, BMS, Celgene, Daiichi-Sankyo, Genomic Health, Lilly, MSD, Novartis, Odonate, Pierre Fabre, Pfizer, Roche, Samsung, Sandoz/Hexal and Seattle Genetics. She has also disclosed fees for non-CME services received directly from commercial interest or their agents with Amgen, AstraZeneca, Daiichi-Sankyo, Lilly, MSD, Novartis, Pierre Fabre, Pfizer and Roche. Prof. Harbeck has also disclosed minority ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with West German Study Group. These financial relationships will not impact her ability to present an unbiased presentation. She intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
Mini-Symposia Speaker	Reuben	Harris	BSc, PhD	Prof. Harris has disclosed consulting fees from ApoGen Biotechnologies. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Daniel F.	Hayes	MD, FASCO, FACP	Dr. Hayes has disclosed royalties from licensed technology with Janssen R&D, LLC (Johnson & Johnson)/transferred to Menarini Silocon Biosystems. Dr. Hayes has also disclosed patents for "A method of predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells as inventor/co-inventor Patent #05725638.0-1223-US2005008602; "Diagnosis and treatment of breast cancer" as inventor/co-inventor Patent #US 8,790,878 B2; "Circulating tumor cell capturing techniques and devices" as inventor/co-inventor Patent #US 8,951,484 B2. Dr. Hayes has also disclosed consultant/advisory panel participant or lecture/honorarium with Cepheid, Freenome, Inc., Artiman Ventures (Cellworks), CVS Caremark Breast Cancer Expert Panel, Agendia, Inc., Lexent Bio, EPIC Sciences, Inc. and Salutogenic Innovations, LLC (SILLC). Dr. Hayes has also disclosed sponsored clinical research-principle or co-investigator with Merrimack Pharmaceuticals, Inc. (Parexel Intl Corp), Eli Lilly Company, Menarini/Silicon BioSystems Veridex (Johnson & Johnson), Puma Biotechnology, Inc. (subcontract Washington University St. Louis to University of Michigan), Pfizer and Astra Zeneca. Dr. Hayes has also disclosed personal financial interest (stock ownership, membership on advisory board, board of directors or other substantive relationships) with Oncimmune LLC (stock options) and Inbiomotion (stock options). Dr. Hayes has also disclosed educational material development with UpToDate (Section Editor, Breast) and MedPage (interviews for broadcast). These financial relationships will impact his ability to present an unbiased presentation.
Educational Session Speaker	Joerg	Heil	MD, PhD	Prof. Heil has no relevant financial relationships with commercial interests to disclose. These financial relationships will not impact his ability to present an unbiased presentation. Prof. Heil intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Educational Session Speaker	Norah Lynn	Henry	MD, PhD	Dr. Henry has disclosed contracted research with Pfizer, Innocrin Pharmaceuticals and AbbVie. She has also disclosed other with Pfizer (writing for abstracts/posters). These financial relationships will not impact her ability to present an unbiased presentation. Dr. Henry intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
SABCS Strategic Planning	Dawn	Hershman	MD	Dr. Hershman has no relevant financial relationships with commercial interests to disclose.
Staff	Sharon	Hill		Ms. Hill has no relevant financial relationships with commercial interests to disclose.
Abstract Panel Chair; Abstract Reviewer	Susan G.	Hilsenbeck		Dr. Hilsenbeck has no relevant financial relationships with commercial interests to disclose.
Panelist	Alice	Ho	MD, MBA	Dr. Ho has disclosed contracted research with Merck and Tesaro. These financial relationships will not impact her ability to present an unbiased presentation.
McGuire Committee	Gabriel N.	Hortobagyi	MD	Dr. Hortobagyi has disclosed consulting fees from Novartis. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Barry	Hudson	PhD	Dr. Hudson has disclosed intellectual property filed regarding the use of RAGE inhibitors in breast cancer. These financial relationships will not impact his ability to present an unbiased presentation.

2020 SABCS Disclosures

Panelist; Abstract Reviewer	Sara A.	Hurvitz	MD, FACP	Dr. Hurvitz has disclosed contracted research with Ambrx, Amgen, Arnivas, Bayer, Daiichi-Sankyo, Genentech/Roche, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics and Dignitana. She has also disclosed other travel and/or editorial services from companies listed above (relating to research). These financial relationships will not impact her ability to present an unbiased presentation. Dr. Hurvitz intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
Educational Session Speaker	E. Shelley	Hwang	MD, MPH	Dr. Hwang has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	James N.	Ingle	MD	Dr. Ingle has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Claudine	Isaacs	MD	Dr. Isaacs has disclosed royalties with Elsevier and Wolters Kluwer. She has also disclosed consulting fees with Novartis, Genentech, Pfizer, PUMA and Seattle Genetics. Dr. Isaacs has also disclosed fees for non-cme services received directly from commercial interest or their agents with Genentech and contracted research with Tesaro paid to the institution. These financial relationships will not impact her ability to present an unbiased presentation.
Program Planning Committee Member, Educational Session Speaker; Abstract Reviewer	Reshma	Jagsi	MD, Dphil	Dr. Jagsi has stock option as compensation for her advisory board role in Equity Quotient, a company that evaluates culture in health care companies; she has received personal fees from Amgen and Vizient and grants for unrelated work from the National Institutes of Health, the Doris Duke Foundation, the Greenwall Foundation, the Komen Foundation, and Blue Cross Blue Shield of Michigan for the Michigan Radiation Oncology Quality Consortium.
Executive Program Planning Committee Member, Special Session Moderator; Educational Session Moderator, Educational Session Speaker	Ismail	Jatoi	MD, PhD	Dr. Jatoi has no relevant financial relationships with commercial interests to disclose. Dr. Jatoi intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Educational Session Speaker	Rinath	Jeselson	MD	
Educational Session Speaker	Rachel	Jimenez	MD	Dr. Jimenez has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Stephen	Johnston	MD, PhD	Prof. Johnston has disclosed consulting fees with Eli Lilly, AstraZeneca, Puma Biotechnology, Pfizer and Novartis. He has also disclosed fees for non-CME services received directly from commercial interest or their agents with Pfizer, Novartis, Eisai, AstraZeneca and Roche/Genentech. Prof. Johnston has also disclosed other Research Funding to Institution: Pfizer, PumaBio, Eli Lilly, AstraZeneca, Novartis and Roche. These financial relationships will not impact his ability to present an unbiased presentation.
Program Planning Committee Member; Clinical Research Moderator	Virginia	Kaklamani	MD, DSc	Dr. Kaklamani has disclosed consulting fees with Amgen, Eisai, Puma, Celldex, AstraZeneca and Athenex. She has also disclosed fees for non-cme services received directly from commercial interest or their agents from Pfizer, Celgene, Genentech, Genomic Health, Puma, Eisai and Novartis. Dr. Kaklamani has also disclosed contracted research with Eisai.
SABCS Strategic Planning; Abstract Reviewer	Kevin	Kalinsky	MD	Dr. Kalinsky has disclosed consulting fees from Biotheranostis, Lilly, Pfizer, Novartis, Eisai and AstraZeneca and contracted research for Incyte, PERS, Genentech, Eli Lilly, Seattle Genetics, Amgen, Letomx and Pfizer. He has also disclosed his spouses ownership interest in Array Biopharma and Pfizer. These financial relationships will not impact his ability to present an unbiased presentation.
SABCS Strategic Planning; Abstract Reviewer	Seema	Khan	MD	Dr. Khan has no relevant financial relationships with commercial interests to disclose.

2020 SABCS Disclosures

Abstract Section Chair; Abstract Reviewer	Tari A.	King	MD	Dr. King has disclosed fees for non-CME services received directly from commercial interest or their agents with Genomic Health/Exact Sciences. These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Section Chair; Abstract Reviewer	Ian	Krop	MD, PhD	Dr. Krop has disclosed consulting fees with Daiichi-Sankyo, Genentech/Roche, MacroGenics, Taiho Oncology, Context Therapeutics and Merck. He has also disclosed contracted research with Genentech/Roche, Daiichi-Sankyo, Pfizer and Taiho Oncology. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Allison	Kurian	MD, MSc	Prof. Kurian has disclosed contracted research with Myriad Genetics (2017-2019). These financial relationships will not impact her ability to present an unbiased presentation.
Program Planning Committee Member	Kate	Lathrop	MD	Dr. Lathrop has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Adrian	Lee	PhD	Dr. Lee has no relevant financial relationships with commercial interests to disclose. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Ann Marilyn	Leitch	MD	Dr. Leitch has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member	M. Kathryn	Leonard	PhD	Ms. Leonard has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Michael	Lewis		
Abstract Reviewer	Christopher	Li	MD, PhD	Dr. Li has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Rong	Li		
Abstract Reviewer	Yi	Li	PhD	Dr. Li has no relevant financial relationships with commercial interests to disclose.
Translational Science Forum Speaker	Shiaw-Yih	Lin	PhD	Dr. Lin has no relevant financial relationships with commercial interests to disclose.
Educational Session Speaker; Abstract Reviewer	Nancy U.	Lin	MD	Dr. Lin has disclosed consulting fees with Puma, Seattle Genetics, Daiichi Sankyo and Denali. She has also disclosed contracted research with Genentech and Seattle Genetics. These financial relationships will not impact her ability to present an unbiased presentation. Dr. Lin intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
Abstract Reviewer	Hannah	Linden	MD	Dr. Linden has no relevant financial relationships with commercial interests to disclose.
McGuire Committee	Marc	Lippman	MD	Prof. Lippman has disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with Seattle Genetics. These financial relationships will not impact his ability to present an unbiased presentation.
Educational Session Speaker; Abstract Reviewer	Jennifer	Litton	MD	Dr. Litton has disclosed royalties from UpToDate and consulting fees from advisory boards of Pfizer and Ayala-but no compensation. Dr. Litton has also disclosed fees for non-cme services received directly from commercial interest or their agents from MedLearning, Physician's Education Resource, Prime Oncology, Medscape and Clinical Care Options. She has also disclosed contracted research from Novartis, Medivation/Pfizer, Genentech, GSK, EMD-Serono, Astra-Zeneca, Medimmune, Zenith, and Jounce, These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Reviewer	Minetta C.	Liu	MD	Dr. Liu has disclosed contracted research with Eisai, Genentech, GRAIL, Merck, Seattle Genetics and Tesaro paid to the Mayo Clinic. These financial relationships will not impact her ability to present an unbiased presentation.

2020 SABCS Disclosures

Educational Session Speaker, Abstract Reviewer	Sherene	Loi	MBBS, FRACP, PhD	Prof. Loi has disclosed consulting fees (paid to the institution) from Aduro Biotech, Novartis, GlaxoSmithKline and G1 Therapeutics. She has also disclosed consulting fees (not compensated) from Seattle Genetics, Pfizer, Novartis, BMS, Merck, AstraZeneca and Roche-Genentech. Prof. Loi has also disclosed contracted research (paid to the institution) from Novartis, Bristol Meyers Squibb, Merck, Roche-Genentech, Puma Biotechnology, Pfizer, Eli Lilly and Seattle Genetics. These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Reviewer	Sibylle	Loibl	MD, PhD	Prof. Loibl has disclosed receipt of intellectual property rights/patent holder pending patent no EP14153692.0. She has also disclosed consulting fees paid to the institution with Abbvie, AstraZeneca, Celgene, Cepheid, Daiichi-Sankyo, Novartis, Pfizer, Roche, Seattle Genetics, Lilly, Eirgenix, BMS, Puma, Pierre-Fabre, MSD and Merck KGaA. Prof. Loibl has also disclosed fees for non-cme services received directly from commercial interest or their agents paid to the institution from Roche, Pfizer, AstraZeneca, Medscape/Prime and personal from Chugai. She has also disclosed contracted research from Eirgenix and AstraZeneca. These financial relationships will not impact her ability to present an unbiased presentation.
Educational Session Speaker	Mathieu	Lupien	PhD	
Abstract Reviewer	Fiona	MacNeill		Dr. MacNeill has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member, Educational Session Moderator	Eleftherios P.	Mamounas	MD, MPH	Dr. Mamounas has disclosed consulting fees from Roche/Genentech, Genomic Health, Inc, Daiichi Sankyo and Biotheranostics. He has also disclosed fees for non-cme services received directly from commercial interest or their agents with Roche/Genentech and Genomic Health, Inc.
SABCS Strategic Planning; Abstract Reviewer	David	Mankoff	MD, PhD	Dr. Mankoff has disclosed a receipt of intellectual property rights/patent holder for Trevarx, Inc where his wife is CEO and consulting fees from Philips, ImaginAb, and Reflexion. He has also disclosed contracted research with Siemens and ownership interest with ImaginAb, Reflexion, and Trevarx (wife).
Abstract Reviewer	Suleiman	Massarweh		
Educational Session Speaker	Ingrid	Mayer	MD, MSCI	Dr. Mayer has disclosed consulting fees with Novartis, Pfizer, Genentech, Lilly, Astra-Zeneca, GSK, Abbvie, Puma, Macrogenics, Immunomedic and Seattle Genetics. She has also disclosed contracted research with Novartis, Pfizer and Genetech. These financial relationships will not impact her ability to present an unbiased presentation. Dr. Mayer intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
Educational Session Speaker	Sandra	McAllister	PhD	
Susan G. Komen® Brinker Award for Scientific Distinction in Basic Science	Donald P.	McDonnell	PhD	Dr. McDonnell has disclosed salary with Duke University School of Medicine and royalty with Radius Health, Zentalis and Celgene. He has also disclosed receipt of intellectual property rights / patent holder with Radius Health and Sermonix. Dr. McDonnell has also disclosed consulting fees with Celgene, G1 Therapeutics, Zentalis, SPV and Therapeutics. He has also disclosed contracted research with Celgene, Novartis, G1 Therapeutics, Zentalis and ownership interest with G1 Therapeutics and Zentalis. Dr. McDonnell intends to reference unlabeled/unapproved uses of drugs in his presentation.
Educational Session Speaker	Sarah	McLaughlin	MD	Dr. McLaughlin has no relevant financial relationships with commercial interests to disclose.
Executive/Program Planning Committee Member	Ruben	Mesa	MD	Dr. Mesa has disclosed consulting fees with Novartis, Sierra Onc, LaJolla and Pharma. He has also disclosed other Research Support: Celgene, Incyte, Abbvie, Samus, Genotech, Promedior and CTI. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Todd W.	Miller	PhD	Dr. Miller has disclosed other grant support from Takeda Pharm for a clinical trial. These financial relationships will not impact his ability to present an unbiased presentation.
Educational Session Speaker	Gordon	Mills	MD, PhD	

2020 SABCS Disclosures

Program Planning Committee Member, Plenary Lecturer; Abstract Reviewer	Elizabeth	Mittendorf	MD, PhD	Dr. Mittendorf has disclosed consulting fees from Merck, and Genomic Health and contracted research with Glaxo Smith Kline. These financial relationships will not impact her ability to present an unbiased presentation.
Educational Session Speaker	Monica	Morrow	MD	Dr. Morrow has disclosed fees for non-cme services received directly from commercial interest or their agents from Genomic Health. These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Section Chair; Abstract Reviewer	Stacy	Moulder	MD	Dr. Moulder has disclosed contracted research with Novartis, Immugen and Bayer. These financial relationships will not impact her ability to present an unbiased presentation.
Program Planning Committee Member; Abstract Reviewer	Julie	Nangia	MD	Dr. Nangia has disclosed consulting fees with Novartis Consultancy. These financial relationships will not impact her ability to present an unbiased presentation.
Educational Session Moderator	Lisa	Newman	MD, MPH	Dr. Newman has no relevant financial relationships with commercial interests to disclose. These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Reviewer	Torsten	Nielsen	MD, PhD, FRCP	Dr. Nielsen has disclosed royalties from nanoString Technologies and Veracyte, Inc. He has also disclosed receipt of intellectual property rights/patent holder with Bioclassifier, LLC. These financial relationships will not impact his ability to present an unbiased presentation.
Educational Session Speaker	Serena	Nik-Zainal	MD, PhD	
Abstract Reviewer	Ruth	O'Regan		Dr. O'Regan has disclosed consulting fees with Novartis, Lilly, Genentech, PUMA, MacroGenics, Immunomedics and Biotheranostics. She has also disclosed contracted research with Eisai, Seattle Genetics, Novartis and PUMA. These financial relationships will not affect her ability to present an unbiased presentation.
Executive Program Planning Committee Member, Year in Review Moderator	C. Kent	Osborne	MD	Dr. Osborne has disclosed consulting fees with AstraZeneca, Lilly, Genetech and Tolmar. These financial relationships will not impact his ability to present an unbiased presentation. Dr. Osborne has no relevant financial relationships with commercial interests to disclose.
Educational Session Speaker	Julie R.	Palmer	ScD, MPH	Dr. Palmer has no relevant financial relationships with commercial interests to disclose.
Clinical Science Forum Speaker	Ben Ho	Park	MD, PhD	Dr. Park has disclosed royalties from Horizon Discovery LTD and consulting fees from Jackson Labs, Pathovax and Celcuity, Inc. He has also disclosed contracted research with GE Healthcare and ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with Celcuity, Inc. Dr. Park has also disclosed other with Tempus, unpaid consultant. These financial relationships will not impact his ability to present an unbiased presentation. Dr. Park intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Basic Science Forum Speaker	Morag	Park	PhD	Prof. Park has no relevant financial relationships with commercial interests to disclose. These financial relationships will not impact her ability to present an unbiased presentation.
Science Forum Speaker	Paul	Parren	PhD	
Educational Session Speaker, Abstract Reviewer	Ann H.	Partridge	MD, MPH	Dr. Partridge has disclosed other with Novartis-Travel Support. These financial relationships will not impact her ability to present an unbiased presentation. She intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
Translational Science Forum Moderator	Mark	Pegram	MD	Dr. Pegram has disclosed consulting fees with Roche/Genentech, AstraZeneca/MedImmune, AstraZeneca/Daiichi, Zymeworks and Seattle Genetics. These financial relationships will not impact his ability to present an unbiased presentation. Dr. Pegram intends to reference unlabeled/unapproved uses of drugs or products in his presentation.

2020 SABCS Disclosures

Abstract Reviewer	Frederique	Penault-Llorca	MD, PhD	Prof. Penault-Llorca has disclosed consulting fees from AstraZeneca, BMS, Janssen, Lilly, Novartis, Pfizer, Roche and Tesaro. These financial relationships will not affect her ability to present an unbiased presentation.
Program Planning Committee Member, Translational Science Forum Speaker; Abstract Section Chair; Abstract Reviewer	Charles K.	Perou	PhD	Dr. Perou has disclosed receipt of intellectual property rights/patent holder and ownership interest in Bioclassifier LLC, and GeneCentric Therapeutics. He has also disclosed royalties from Bioclassifier LLC and consulting fees from G1 Therapeutics, Ionis Pharmaceuticals, Nanostring Technologies, Bioclassifier LLC, and GeneCentric Therapeutics. These financial relationships will not impact his ability to present and unbiased presentation.
Abstract Reviewer	Liane	Philpotts	MD	Dr. Philpotts has no relevant financial relationships with commercial interests to disclose.
Panelist	Martine J.	Piccart-Gebhart	MD, PhD	Prof. Piccart-Gebhart has disclosed consulting fees from Oncolytics, AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, and G1 Therapeutics. She has also disclosed contracted research with AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier and Synthron. These financial relationships will not impact her ability to present an unbiased presentation. Prof. Piccart-Gebhart intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
Year in Review Speaker	Helen	Piwnic-Worms	PhD	Dr. Piwnica-Worms has no relevant financial relationships with commercial interests to disclose.
Executive/Program Planning Committee Member	Dean	Post	BS	Mr. Post has no relevant financial relationships with commercial interests to disclose.
Educational Session Speaker	Aleix	Prat	MD, PhD	Prof. Prat has disclosed consulting fees with Nanostring Technologies, Roche, Novartis, Pfizer, Oncolytics Biotech, Amgen, Lilly and MSD. He also had disclosed contracted research with Roche Farma, SA Novartis Farma, SA Sysmex Europe GmbH Medica Scientia inno, and research. Prof. Prat has also disclosed other with Nanostring Technologies, Roche and Novartis. These financial relationships will not impact his ability to present an unbiased presentation.
Educational Session Speaker; Abstract Section Chair; Abstract Program Planning Committee Member, Educational Program Planning Committee Member, Educational Session Speaker	Lajos	Pusztai	MD, DPhil	Prof. Pusztai has disclosed consulting fees from Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, Genetech, Eisai, Pieris, Immunomedics, Seattle Genetics, Clovis, Syndax, H3Bio and Daiichi. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Sughra	Raza	MD	Dr. Raza has no relevant financial relationships with commercial interests to disclose.
Panelist	Meredith	Regan	SCD	Dr. Regan has disclosed consulting fees with BMS and contracted research As Dir. IBCSG Stats and DM Center, she oversee clinical trials funded by (and/or provision of drug supply): Novartis, Pfizer, Ipsen, AstraZeneca, Pierre Fabre, Roche, TerSera. Dr. Regan has research funding (institution) from Bayer, BMS. These financial relationships will not impact her ability to present an unbiased presentation.

2020 SABCS Disclosures

Abstract Reviewer	Jorge	Reis-Filho		Dr. Reis-Filho has disclosed consulting fees from Goldman Sachs, REPARE Therapeutics and Paige.AI, a member of the scientific advisory board of Volition Rx and Paige.AI, and an ad hoc member of the scientific advisory board of Ventana Medical Systems, Roche Tissue Diagnostics, Genentech, Novartis and InVivo. These financial relationships will not impact his ability to present an unbiased presentation.
Program Planning Committee Member, Educational Program Meeting	Andrea L.	Richardson	MD, PhD	Dr. Richardson has disclosed receipt of intellectual property rights / patent holder with Myriad Genetics. These financial relationships will not impact her ability to present and unbiased presentation.
Committee Member, SABCS Strategic Planning, Educational	Mothaffar F.	Rimawi	MD	Dr. Rimawi has disclosed consulting fees with Genentech, Macrogenics and Seattle Genetics. He has also disclosed contracted research with Pfizer and GSK. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	David	Rimm	MD, PhD	Dr. Rimm has disclosed royalties with Rarecyte and receipt of intellectual property rights/patent holder with Yale. He has also disclosed consulting fees with Astra Zeneca, Cell Signaling Technology, Cepheid, Konica/Minolta, Merck, NextCure, Odonate, PAIGE.AI and Sanofi. Dr. Rimm has also disclosed contracted research with Amgen, Cepheid, Navigate Biopharma, Nextcure, Konica/Minolta and Lilly. These financial relationships will not impact his ability to present an unbiased presentation.
Panelist	Valencia	Robinson		
Translational Science Forum Moderator	Jeffrey	Rosen	PhD	Dr. Rosen has no relevant financial relationships with commercial interests to disclose.
Educational Session Speaker	Kathryn	Ruddy	MD, MPH	
McGuire Committee, Abstract Section Chair; Abstract Reviewer	Hope S.	Rugo	MD, FASCO	Dr. Rugo has disclosed consulting fees from Puma and Samsung (limited consulting). She has also disclosed contracted research with Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi, Seattle Genetics, Eisai, Macrogenics and Immunomedics. Dr. Rugo has also disclosed other travel support with Daiichi, Mylan, Pfizer, Merck, AstraZeneca, Novartis and Macrogenics. These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Reviewer	Tara	Sanft	MD	Dr. Sanft has no relevant financial relationships with commercial interests to disclose. These financial relationships will not impact her ability to present an unbiased presentation.
Special Session Speaker	Rengaswamy	Sankaranarayanan	MD, MBBS	
Program Planning Committee Member, Educational Session	Rachel	Schiff	PhD	Dr. Schiff has disclosed royalty with Wolters Kluwer/ UpToDate and consulting fees from MacroGenomics. She has also disclosed contracted research with PUMA, Gilead and AstraZeneca. These financial relationships will not impact her ability to present an unbiased presentation.
Abstract Reviewer	Robert J.	Schneider	PhD	Dr. Schneider has disclosed consulting fees with eFFECTOR Therapeutics, MBQ Pharma, PTC Therapeutics, Cytonus and ENB Therapeutics. He has also disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with eFFECTOR Therapeutics, MBQ Pharma, PTC Therapeutics, Cytonus and ENB Therapeutics. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Stuart	Schnitt	MD	Dr. Schnitt has disclosed consulting fees with PathAI. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Section Chair; Abstract Reviewer	Karla	Sepulveda		Dr. Sepulveda has no relevant financial relationships with commercial interests to disclose. She intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
Abstract Reviewer	Ivana	Sestak	MD	Dr. Sestak has disclosed other lecture fees from Myriad Genetics. These financial relationships will not impact her ability to present an unbiased presentation.

2020 SABCS Disclosures

Abstract Reviewer	Dennis	Sgroi	MD	Dr. Sgroi has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Priyanka	Sharma	MD	Dr. Sharma has disclosed consulting fees with Novartis, Merck, Seattle Genetics, Exact Biosciences and Epic Biosciences. She has also disclosed contracted research with Novartis, Celgene, Bristol-Myers Squibb and Merck for research funding. These financial relationships will not impact her ability to present an unbiased presentation.
Plenary Lecturer	Norman E.	Sharpless	MD	
Executive Program Planning Committee	Stephanie	Shelton		Ms. Shelton has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	William M.	Sikov	MD	Dr. Sikov has disclosed fees for non-CME services received directly from commercial interestor their agents with Lilly Oncology, Eisai and Daiichi Sankyo. These financial relationships will not impact his ability to present an unbiased presentation.
Program Planning Committee Member; Abstract Section Chair; Abstract Reviewer	Kalliopi P.	Siziopikou	MD, PhD	Dr. Siziopikou has no relevant financial relationships with commercial interests to disclose.
SABCS Strategic Planning; Abstract Reviewer	Christos	Sotiriou	MD, PhD	Prof. Sotiriou has disclosed consulting fees from Astellas, Cepheid, Vertex, Seattle Genetics, Puma, Amgen, and Merck & Co., Inc. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Joseph	Sparano	MD	Dr. Sparano has disclosed consulting fees with Roche, Celgene, Pfizer, Novartis and CStone. He has also disclosed contracted research with Deciphera and Prescient Therapeutics. These financial relationships will not impact his ability to present an unbiased presentation. Dr. Sparano intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Abstract Reviewer	Sandi	Stanford	BA	Ms. Sanford has no relevant financial relationships with commerical interests to disclose. She intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
Mini-Symposia Speaker	Mike	Stratton	FMedSci, FRS	
Abstract Reviewer	Patrick	Sung	PhD	Dr. Sung has no relevant financial relationships with commerical interests to disclose.
Abstract Section Chair; Abstract Reviewer	Fraser	Symmans		Prof. Symmans has disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with Delphi Diagnostics, Inc. and Ionis Pharmaceuticals. These financial relationships will not impact his ability to present an unbiased presentation. Prof. Symmans intends to reference unlabeled/unaproved uses of drugs or products in his presentation.
Abstract Reviewer	Shou-Ching	Tang	MD, PhD, FACP, FRCPC	Dr. Tang has no relevant financial relationships with commercial interests to disclose.
Abstract Reviewer	Melinda	Telli		
Abstract Reviewer	Mary Beth	Terry	PhD	Dr. Terry has no relevant financial relationships with commerical interests to disclose.
Program Planning Committee Member; Abstract Reviewer	Alastair M.	Thompson	BSc (HONS), MB ChB, MD, FRCSEd	Dr. Thompson has no relevant financial relationships with commercial interests to disclose. He intends to reference unlabeled/unapproved uses of drugs or products in his presentation.

2020 SABCS Disclosures

Abstract Reviewer	Sara	Tolaney	MD, MPH	Dr. Tolaney has disclosed consulting fees and contracted research (support goes to the institution) with AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Cyclacel, Sanofi, Celldex, Paxman, Odonate, Seattle Genetics, Silverback Therapeutics, G1 Therapeutics, Abbvie, Anthenex and OncoPep. These financial relationships will not impact her ability to present an unbiased presentation. Dr. Tolaney intends to reference unlabeled/unapproved uses of drugs or products in her presentation.
Abstract Reviewer	Debasish (Debu)	Tripathy	MD	Dr. Tripathy has disclosed consulting fees with Pfizer, AstraZeneca, Genomic Health and OncoPep. He has also disclosed contracted research with Novartis and Polyphor.
Clinical Research Workshop Speaker; Abstract Reviewer	Nicholas	Turner	MD, PhD	Prof. Turner has received advisory board honoraria from AstraZeneca, Bristol-Myers Squibb, Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, Roche/Genentech, Bicycle Therapeutics, Taiho, Zeno Pharmaceuticals, Repare Therapeutics and research funding from AstraZeneca, BioRad, Pfizer, Roche/Genentech, Clovis, Merck Sharpe and Dohme and Guardant Health.
Mini-Symposia Speaker	Andrew	Tutt	PhD, MB ChB	
Abstract Reviewer	Naoto T.	Ueno	MD, PhD, FACP	Dr. Ueno has disclosed consulting fees with Daiichi-Sankyo. He has also disclosed contracted research with PUMA Oncology, Pfizer, Amgen, Merck and Oncotherapy. These financial relationships will not impact hsi ability to present an unbiased presentation.
Abstract Reviewer	Jane	Visvader		Dr. Visvader has disclosed royalties from Venetoclax. These financial relationships will not impact her ability to present an unbiased presentation.
Panelist, Moderator	Steven	Vogl	MD	Dr. Vogl has disclosed consulting fees from Animated Dynamics. He has also disclosed ownership interest (stocks, stock options or other ownership interest excluding diversified mutual funds) with Amgen and Bristol-Myers Squibb. These financial relationships will not impact his ability to present an unbiased presentation. Dr. Vogl intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Abstract Reviewer	Nikhil	Wagle	MD	Dr. Wagle has disclosed consulting fees with Eli Lilly and Relay Therapeutics. He has also disclosed contracted research with Puma Technology. Dr. Wagle has also disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) with Relay Therapeutics. These financial relationships will not impact his ability to present an unbiased presentation.
Basic Science Forum Speaker	Jennifer A.	Wargo	MD, MMSc	Dr. Wargo has disclosed receipt of intellectual property rights/patent holder as an inventor on a US patent application (PCT/US17/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance immune checkpoint blockade responses by modulating the microbiome. She has also disclosed consulting fees (speaker's bureau and honoraria) with Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, Exelixis, Bristol-Myers Squibb and she serves as a consultant / advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals and Microbiome DX. Dr. Wargo has also disclosed contracted research with GlaxoSmithKline, Roche/Genentech, Bristol-Myers Squibb and Novartis. She has also disclosed ownership interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) for stock options in Ela Therapeutics. These financial relationships will not impact her ability to present an unbiased presentation.
Program Planning Committee Member, SABCS Strategic Planning, McGuire	Eric P.	Winer	MD	Dr. Winer has disclosed consulting fees with Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Genomic Health, GSK, Jounce, Leap, Lilly, Novartis and Seattle Genetics. He has also disclosed contracted research with Genetech/Roche. These financial relationships will not impact his ability to present an unbiased presentation.
Session Moderator; Abstract Section Chair; Abstract Reviewer	Wendy	Woodward	MD, PhD	Dr. Woodward has disclosed consulting fees from Genomic Health and Epic Sciences. These financial relationships will not impact her ability to present an unbiased presentation.

2020 SABCS Disclosures

Educational Session Speaker	Jean L.	Wright	MD	Dr. Wright has disclosed salary with Johns Hopkins (Jean) and NIH (spouse). She has also disclosed royalty Up To Date (Spouse). These financial relationships will not impact her ability to present an unbiased presentation.
Program Planning Committee Member	Victor (Trey)	Ximenez		Mr. Ximenez has no relevant financial relationships with commercial interests to disclose.
Educational Session Speaker	Jing	Yang	PhD	
Program Planning Committee Member, Mini-Symposia Moderator; Abstract Section Chair; Abstract Reviewer	Douglas	Yee	MD	Dr. Yee has disclosed consulting fees from Puma Oncology and Martell Diagnostics. He has also disclosed contracted research with coordinating investigator for Boehringer Ingelheim phase 1B study of xentuzamab. Dr. Yee has disclosed ownership interest with Apogen Biotechnologies stock, no product and no stock value. He has also disclosed other Leadership Role in I-SPY 2 trial, Faculty and Committee for PER Int Breast Congress. These financial relationships will not impact his ability to present an unbiased presentation.
Abstract Reviewer	Richard	Zellars		Dr. Zellars has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member, Educational Session	Xiang	Zhang	PhD	Dr. Zhang has no relevant financial relationships with commercial interests to disclose.